Allorion Therapeutics pipeline focuses on next-generation small molecule targeted therapies for oncology and autoimmune diseases.
ARTS-011 is a highly selective potent oral TYK2 allosteric inhibitor positioned for inflammatory disorders including psoriasis and lupus. The China CDE cleared its IND application in April 2023 and a Phase 1 study in healthy volunteers has been completed in China.
ARTS-021, now AVZO-021 after global licensing to Avenzo Therapeutics in January 2024, is a potent selective CDK2 inhibitor. It targets HR+/HER2- breast cancer and CCNE1-amplified solid tumors. FDA IND clearance occurred in May 2023 with first patient dosed in the ongoing Phase 1/2 trial in October 2023.
The premier EGFR L858R allosteric inhibitor program received an exclusive option and global license from AstraZeneca in January 2024. This supports development against activating EGFR mutations often seen in lung cancers, potentially in combination with existing therapies.
Discovery is powered by validated allosteric screening using mass spec, synthetic lethality platforms leveraging CRISPR and phenotypic assays, an AI-enabled data platform, and a proprietary library of nearly 200,000 compounds. Additional programs are advancing toward clinical candidate selection.
